Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality?

Author(s): Orazio Caffo, Andrea Lunardi, Chiara Trentin, Francesca Maines, Antonello Veccia and Enzo Galligioni

Volume 17, Issue 11, 2016

Page: [1301 - 1308] Pages: 8

DOI: 10.2174/1389450117666160101121317

Price: $65


The availability of new drugs capable of improving the overall survival of patients with metastatic castration-resistant prostate cancer has led to the possibility of using them sequentially in the hope of obtaining a cumulative survival benefit. The new agents have already been administered as third-line treatments in patients who have previously received them as second line in everyday clinical practice, but the efficacy of this practice is not yet supported by clinical trial data, and evidence of possible cross-resistance has reinforced the debate concerning the best sequence to use in order to maximise the benefit. Furthermore, the situation is further complicated by the possibility of administering new hormonal agents to chemotherapy-naïve patients, and novel chemotherapeutic agents to hormone-sensitive patients. This article critically reviews the available data concerning the sequential use of new drugs, and discusses the real evidence concerning their optimal positioning in the therapeutic strategy of metastatic castration-resistant prostate cancer.

Keywords: Castration-resistant prostate cancer, sequence, first-line, second-line, docetaxel, abiraterone acetate, cabazitaxel. enzalutamide.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy